Vertex Pharmaceuticals (VRTX) Accounts Payables (2009 - 2026)

Vertex Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $489.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 9.96% year-over-year to $489.3 million in Q1 2026; TTM through Mar 2026 was $489.3 million, a 9.96% increase from a year earlier, with the FY2025 full-year figure at $461.7 million, up 11.79% from the prior year.
• Accounts Payables advanced to $489.3 million in Q1 2026 per VRTX's latest filing, from $461.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $489.3 million in Q1 2026 and bottomed at $126.9 million in Q3 2022.
• The 5-year median for Accounts Payables is $364.9 million (2023), against an average of $351.5 million.
• Across the five-year window, Accounts Payables jumped 196.22% in 2023 and dropped 9.67% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $303.9 million in 2022, then gained by 20.07% to $364.9 million in 2023, then advanced by 13.18% to $413.0 million in 2024, then increased by 11.79% to $461.7 million in 2025, then climbed by 5.98% to $489.3 million in 2026.
• Per Business Quant, the three latest VRTX Accounts Payables figures stand at $489.3 million (Q1 2026), $461.7 million (Q4 2025), and $420.3 million (Q3 2025).